Abbott Laboratories (NYSE: ABT) has a higher price-to-earnings ratio of 34.94x compared to its average ratio. ABT has 36-month beta value of 0.73. Analysts have mixed views on the stock, with 13 analysts rating it as a “buy,” 8 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for ABT is 1.72B, and currently, short sellers hold a 0.70% ratio of that float. The average trading volume of ABT on December 10, 2024 was 5.08M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ABT) stock’s latest price update
The stock of Abbott Laboratories (NYSE: ABT) has decreased by -0.61 when compared to last closing price of 115.60. Despite this, the company has experienced a -1.64% fall in its stock price over the last five trading sessions. prnewswire.com reported 2024-12-07 that Nearly 20,000 Big Ten students, alumni and fans across the country donated blood as part of the Abbott-Big Ten nationwide competition this college football season, helping save as many as 60,000 lives Nebraska’s win was announced at the Discover Big Ten Football Championship Game where the university received $1 million from global healthcare company Abbott to advance student and community health The competition, which will be back next fall, aims to help combat the greatest need for blood in a generation, while also helping create new lifelong blood donors ABBOTT PARK, Ill., and INDIANAPOLIS, Dec. 7, 2024 /PRNewswire/ — This college football season, Abbott (NYSE: ABT) and the Big Ten put fandom and the hearts of Big Ten communities to the test with their inaugural blood donation competition, “The We Give Blood Drive.
ABT’s Market Performance
Abbott Laboratories (ABT) has experienced a -1.64% fall in stock performance for the past week, with a -0.35% drop in the past month, and a -1.89% drop in the past quarter. The volatility ratio for the week is 1.33%, and the volatility levels for the past 30 days are at 1.47% for ABT. The simple moving average for the past 20 days is -1.56% for ABT’s stock, with a 3.57% simple moving average for the past 200 days.
Analysts’ Opinion of ABT
Many brokerage firms have already submitted their reports for ABT stocks, with Oppenheimer repeating the rating for ABT by listing it as a “Outperform.” The predicted price for ABT in the upcoming period, according to Oppenheimer is $130 based on the research report published on October 08, 2024 of the current year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see ABT reach a price target of $131. The rating they have provided for ABT stocks is “Overweight” according to the report published on September 19th, 2024.
ABT Trading at -1.00% from the 50-Day Moving Average
After a stumble in the market that brought ABT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -5.54% of loss for the given period.
Volatility was left at 1.47%, however, over the last 30 days, the volatility rate increased by 1.33%, as shares sank -1.45% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.20% upper at present.
During the last 5 trading sessions, ABT fell by -1.64%, which changed the moving average for the period of 200-days by -3.82% in comparison to the 20-day moving average, which settled at $116.72. In addition, Abbott Laboratories saw 4.39% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ABT starting from Funck, Jr. Robert E., who proposed sale 15,000 shares at the price of $120.00 back on Nov 04 ’24. After this action, Funck, Jr. Robert E. now owns shares of Abbott Laboratories, valued at $1,800,000 using the latest closing price.
ALLEN HUBERT L, the EXECUTIVE VICE PRESIDENT of Abbott Laboratories, sale 157,421 shares at $117.04 during a trade that took place back on Oct 21 ’24, which means that ALLEN HUBERT L is holding 184,806 shares at $18,424,298 based on the most recent closing price.
Stock Fundamentals for ABT
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.55 for the gross margin
The net margin for Abbott Laboratories stands at 0.14. The total capital return value is set at 0.12. Equity return is now at value 14.87, with 7.85 for asset returns.
Based on Abbott Laboratories (ABT), the company’s capital structure generated 0.27 points at debt to capital in total, while cash flow to debt ratio is standing at 0.58. The debt to equity ratio resting at 0.38. The interest coverage ratio of the stock is 13.9.
Currently, EBITDA for the company is 10.61 billion with net debt to EBITDA at 0.69. When we switch over and look at the enterprise to sales, we see a ratio of 5.02. The receivables turnover for the company is 4.48for trailing twelve months and the total asset turnover is 0.55. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.60.
Conclusion
To put it simply, Abbott Laboratories (ABT) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
